Info

31. Smith BD, Levis M, Beran M, et al.: Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103:3669-3676, 2004.

32. Roboz G, List A, Giles F, et al.: Phase I trial of PTK787/ZK 222584, an inhibitor of vascular growth factor receptor tyrosine kinases, in acute myeloid leukemia and myelodysplastic syndrome [abstract]. Blood 100:337a, 2002.

33. Giles FJ, Stopeck AT, Silverman LR, et al.: SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102:795-801, 2003.

34. Kantarjian HM, O'Brien S, Cortes J, et al.: Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98:522-528, 2003.

35. Issa J-P, Garcia-Manero G, Giles F, et al.: Phase 1 study of low-dose prolonged exposure schedules of the hypo-methylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640,

0 0

Post a comment